Tatton-Brown-Rahman overgrowth syndrome: genes and variants
Explore variant evidence for Tatton-Brown-Rahman overgrowth syndrome across 1 analyzed protein (DNMT3A). Linked ClinVar records include 32 pathogenic or likely pathogenic variants, 157 variants of uncertain significance and 19 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-04. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Tatton-Brown-Rahman overgrowth syndrome
DNMT3A: DNA (cytosine-5)-methyltransferase 3A
It establishes new DNA methylation patterns during development and hematopoietic differentiation. Somatic variants are common in clonal hematopoiesis and acute myeloid leukemia, while germline variants cause Tatton-Brown-Rahman overgrowth syndrome.
32 ClinVar pathogenic / likely pathogenic and 176 uncertain variants in DNMT3A have source records linked to Tatton-Brown-Rahman overgrowth syndrome. Association strength is not clinical gene validity.
Where Tatton-Brown-Rahman overgrowth syndrome variants cluster
- DNMT3A SAM-dependent MTase C5-type (positions 634–912): 17 of 29 ClinVar pathogenic / likely pathogenic variants, 1.9× more than its size predicts (a length-based count, not a validated hotspot).
- DNMT3A Interaction with the PRC2/EED-EZH2 complex (positions 494–586): 8 of 29 ClinVar pathogenic / likely pathogenic variants, 2.7× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Tatton-Brown-Rahman overgrowth syndrome
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| DNMT3A R771Q | 771 | SAM-dependent MTase C5-type | Pathogenic / likely pathogenic (★★) |
| DNMT3A L508P | 508 | ADD | Pathogenic / likely pathogenic (★★) |
| DNMT3A R659C | 659 | SAM-dependent MTase C5-type | Pathogenic / likely pathogenic (★★) |
| DNMT3A Y660H | 660 | SAM-dependent MTase C5-type | Pathogenic / likely pathogenic (★★) |
| DNMT3A R736H | 736 | SAM-dependent MTase C5-type | Pathogenic / likely pathogenic (★★) |
| DNMT3A R659H | 659 | SAM-dependent MTase C5-type | Pathogenic / likely pathogenic (★★) |
| DNMT3A R749C | 749 | SAM-dependent MTase C5-type | Pathogenic / likely pathogenic (★★) |
| DNMT3A S770L | 770 | SAM-dependent MTase C5-type | Pathogenic / likely pathogenic (★★) |
| DNMT3A R882C | 882 | SAM-dependent MTase C5-type | Pathogenic / likely pathogenic (★★) |
| DNMT3A P904L | 904 | SAM-dependent MTase C5-type | Pathogenic / likely pathogenic (★★) |
| DNMT3A R882H | 882 | SAM-dependent MTase C5-type | Pathogenic / likely pathogenic (★★) |
| DNMT3A G543R | 543 | ADD | Pathogenic / likely pathogenic (★) |
| DNMT3A G543S | 543 | ADD | Pathogenic / likely pathogenic (★) |
| DNMT3A R736L | 736 | SAM-dependent MTase C5-type | Pathogenic / likely pathogenic (★) |
| DNMT3A R771G | 771 | SAM-dependent MTase C5-type | Pathogenic / likely pathogenic (★) |
| DNMT3A K299Q | 299 | PWWP | Pathogenic / likely pathogenic (★) |
| DNMT3A P307L | 307 | PWWP | Pathogenic / likely pathogenic (★) |
| DNMT3A C586F | 586 | ADD | Pathogenic / likely pathogenic (★) |
| DNMT3A D702G | 702 | SAM-dependent MTase C5-type | Pathogenic / likely pathogenic (★) |
| DNMT3A G726V | 726 | SAM-dependent MTase C5-type | Pathogenic / likely pathogenic (★) |
| DNMT3A T832I | 832 | SAM-dependent MTase C5-type | Pathogenic / likely pathogenic (★) |
| DNMT3A L373P | 373 | Interaction with DNMT1 and DNMT3B | Pathogenic / likely pathogenic (★) |
| DNMT3A E545G | 545 | ADD | Pathogenic / likely pathogenic (★) |
| DNMT3A C557R | 557 | ADD | Pathogenic / likely pathogenic (★) |
| DNMT3A R729Q | 729 | SAM-dependent MTase C5-type | Pathogenic / likely pathogenic (★) |
| DNMT3A Q842R | 842 | SAM-dependent MTase C5-type | Pathogenic / likely pathogenic (★) |
| DNMT3A C494S | 494 | ADD | Pathogenic / likely pathogenic (★) |
| DNMT3A I310N | 310 | PWWP | Pathogenic / likely pathogenic |
| DNMT3A M548K | 548 | ADD | Pathogenic / likely pathogenic |
| DNMT3A L648P | 648 | SAM-dependent MTase C5-type | Pathogenic / likely pathogenic |
| DNMT3A F902S | 902 | SAM-dependent MTase C5-type | Pathogenic / likely pathogenic |
| DNMT3A I158N | 158 | Pathogenic / likely pathogenic |
Uncertain variants prioritized for review in Tatton-Brown-Rahman overgrowth syndrome
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| DNMT3A C586Y | 586 | ADD | Uncertain (★) | +7: C586F at the same position is pathogenic; seen in 6.6e-06 of gnomAD DNA copies; REVEL 0.948 |
| DNMT3A R749S | 749 | SAM-dependent MTase C5-type | Uncertain (★) | +7: in a 3D region that tolerates change poorly (1R); R749C at the same position is pathogenic; seen in 2e-06 of gnomAD DNA copies; REVEL 0.883 |
| DNMT3A R882S | 882 | SAM-dependent MTase C5-type | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; R882C at the same position is pathogenic; REVEL 0.884 |
| DNMT3A R736C | 736 | SAM-dependent MTase C5-type | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; R736L at the same position is pathogenic; REVEL 0.923 |
Which prediction tools work for Tatton-Brown-Rahman overgrowth syndrome
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- VARITY: 99 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 98 out of 100
- CATVariant: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- REVEL: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 96 out of 100
- PolyPhen-2: 95 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CADD: 93 out of 100
- phyloP: 89 out of 100
- SIFT: 83 out of 100
- MetaSVM: 81 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 74 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- phastCons: 68 out of 100
- Pangolin: 46 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Heyn-Sproul-Jackson syndrome also has ClinVar records linked to DNMT3A variants; they fall partly in the same places as the Tatton-Brown-Rahman overgrowth syndrome variants (5 pathogenic / likely pathogenic).
Diseases related to Tatton-Brown-Rahman overgrowth syndrome
- Acute myeloid leukemia, also linked to DNMT3A
- Multiple myeloma, also linked to DNMT3A
- Paediatric disorders, also linked to DNMT3A
- Heyn-Sproul-Jackson syndrome, also linked to DNMT3A
- Rare genetic intellectual disability, also linked to DNMT3A
- Ebv-positive nodal t- and nk-cell lymphoma, also linked to DNMT3A
Frequently asked questions
Which genes have records linked to Tatton-Brown-Rahman overgrowth syndrome?
This view contains 1 analyzed proteins: DNMT3A. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 32 pathogenic or likely pathogenic variants, 157 variants of uncertain significance and 19 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 4 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 252 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center